Search Results for "Pain"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pain. Results 81 to 90 of 279 total matches.

Intravesical Gemcitabine (Inlexzo) for Bladder Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 27, 2025  (Issue 1740)
Effects: Urinary frequency and urgency, urinary tract infection and pain, dysuria, and hematuria ...
The FDA has approved Inlexzo, a gemcitabine intravesical system, for treatment of Bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors. The Inlexzo system is placed into the bladder to deliver gemcitabine for 3 weeks.
Med Lett Drugs Ther. 2025 Oct 27;67(1740):e176-7   doi:10.58347/tml.2025.1740c |  Show IntroductionHide Introduction

Comparison Table: Some Oral Anticoagulants for VTE (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
: Vasculitis, chills, alopecia, pruritus, urticaria, abdominal pain, bloating, nausea, vomiting, diarrhea ...
View the Comparison Table: Some Oral Anticoagulants for VTE
Med Lett Drugs Ther. 2022 Jul 25;64(1655):e122-4 |  Show IntroductionHide Introduction

Teprotumumab (Tepezza) for Thyroid Eye Disease

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
, that can cause eye pain, dryness, redness and swelling, diplopia, and in severe cases, loss of vision ...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, has been approved by the FDA for IV treatment of thyroid eye disease. It is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2021 May 31;63(1625):87-8 |  Show IntroductionHide Introduction

Tretinoin/Benzoyl Peroxide Cream (Twyneo) for Acne

   
The Medical Letter on Drugs and Therapeutics • May 16, 2022  (Issue 1650)
trials included applicationsite pain (10.6%), dryness (4.9%), exfoliation (4.1%), erythema (4.0 ...
The FDA has approved Twyneo (Galderma), a cream containing the retinoid tretinoin and the oxidizing agent benzoyl peroxide, for once-daily topical treatment of acne in patients ≥9 years old.
Med Lett Drugs Ther. 2022 May 16;64(1650):75-6 |  Show IntroductionHide Introduction

A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022  (Issue 1656)
, and pain, muscle spasms, insomnia, abdominal pain, constipation, diarrhea, dizziness, abnormal dreams ...
A once-weekly transdermal formulation of the acetylcholinesterase inhibitor donepezil (Adlarity – Corium) has been approved by the FDA for treatment of mild, moderate, and severe Alzheimer's disease (AD) dementia. Donepezil is the second acetylcholinesterase inhibitor to become available in a transdermal formulation; transdermal rivastigmine (Exelon Patch), which is applied once daily, has been available for years for the same indication. Donepezil is also available in oral formulations (Aricept, and generics) for treatment of AD dementia.
Med Lett Drugs Ther. 2022 Aug 8;64(1656):e128-9 |  Show IntroductionHide Introduction

Opill — An OTC Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
, breast tenderness, increased appetite, abdominal pain, and headache can occur. Dosage: One 0.075 mg ...
The FDA has approved Opill (Perrigo), a progestin-only oral contraceptive that contains norgestrel, for sale over the counter (OTC). Opill is the first oral contraceptive to be approved in the US for sale without a prescription. Approval of OTC Opill is intended to increase access to effective contraception and reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2   doi:10.58347/tml.2023.1685c |  Show IntroductionHide Introduction

Berdazimer Gel (Zelsuvmi) for Molluscum Contagiosum

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
: Application-site pain and erythema are common. ▶ Dosage: Applied to each lesion once daily for up to 12 ...
Berdazimer 10.3% gel (Zelsuvmi – Ligand), a first-in-class nitric oxide-releasing agent, has been approved by the FDA for topical treatment of molluscum contagiosum in patients ≥1 year old. It is the second drug to become available in the US for treatment of molluscum contagiosum and the first that can be applied by the patient or caregiver at home; cantharidin 0.7% solution (Ycanth), which is applied by a healthcare professional, was approved earlier for use in patients ≥2 years old.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):113-4   doi:10.58347/tml.2025.1733a |  Show IntroductionHide Introduction

Acoramidis (Attruby) for Transthyretin Amyloid Cardiomyopathy

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025  (Issue 1724)
: Most common were diarrhea and upper abdominal pain. Increases in serum creatinine and decreases ...
The FDA has approved acoramidis (Attruby – BridgeBio), an oral transthyretin stabilizer, to reduce cardiovascular-related hospitalization and cardiovascular death in adults with wild-type or variant (hereditary) transthyretin amyloid cardiomyopathy (ATTR-CM). Acoramidis is the second transthyretin stabilizer to be approved in the US for this indication; tafamidis (Vyndaqel, Vyndamax) was approved in 2019.
Med Lett Drugs Ther. 2025 Mar 17;67(1724):45-6   doi:10.58347/tml.2025.1724c |  Show IntroductionHide Introduction

Avmapki Fakzynja Co-Pack for Ovarian Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
: Nausea, fatigue, rash, diarrhea, musculoskeletal pain, edema, and serious skin reactions were reported ...
Avmapki Fakzynja Co-Pack (Verastem), a combination of the kinase inhibitors avutometinib and defactinib, has received accelerated approval from the FDA for treatment of KRAS-mutated recurrent low-grade serous ovarian cancer in women who had previously received systemic therapy. Neither drug is approved for use as monotherapy for any indication. Avmapki Fakzynja is the first treatment to be approved in the US for this indication.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e120-1   doi:10.58347/tml.2025.1733j |  Show IntroductionHide Introduction

Retifanlimab (Zynyz) for Anal Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
, musculoskeletal pain, pruritus, diarrhea, rash, pyrexia, nausea, and urinary tract infection. Infusion-related ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed death receptor-1 (PD-1)-blocking antibody, has been approved by the FDA for use in combination with carboplatin and paclitaxel for first-line treatment of unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as monotherapy in patients who had disease progression or intolerance to platinum-based chemotherapy. The drug received accelerated approval for treatment of recurrent locally advanced or metastatic Merkel cell carcinoma in 2023.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):e126-7   doi:10.58347/tml.2025.1733m |  Show IntroductionHide Introduction